Reference
Fossard G, et al. Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patients. Haematologica 101: e86-e90, No. 3, Jan 2016. Available from: URL: http://doi.org/10.3324/haematol.2015.135103 - France
Rights and permissions
About this article
Cite this article
Nilotinib. Reactions Weekly 1658, 347 (2017). https://doi.org/10.1007/s40278-017-32543-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-017-32543-5